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ABSTRACT 22 
The placenta is the main determinant of fetal growth and development in utero. It supplies all the 23 
nutrients and oxygen required for fetal growth and secretes hormones that facilitate maternal 24 
allocation of nutrients to the fetus. Furthermore, the placenta responds to nutritional and metabolic 25 
signals in the mother by altering its structural and functional phenotype which can lead to changes in 26 
maternal resource allocation to the fetus. The molecular mechanisms by which the placenta senses 27 
and responds to environmental cues are poorly understood. This review discusses the role of the 28 
insulin-like growth factors (IGFs) in controlling placental resource allocation to fetal growth, 29 
particularly in response to adverse gestational environments. In particular, it assesses the impact of 30 
the IGFs and their signalling machinery on placental morphogenesis, substrate transport and 31 
hormone secretion, primarily in the laboratory species, although it draws on data from human and 32 
other species where relevant. It also considers the role of the IGFs as environmental signals in linking 33 
resource availability, to fetal growth through changes in the morphological and functional 34 
phenotype of the placenta. As altered fetal growth is associated with increased perinatal morbidity 35 
and mortality and a greater risk of developing adult-onset diseases in later life, understanding the 36 
role of IGFs during pregnancy in regulating placental resource allocation to fetal growth is important 37 
for identifying the mechanisms underlying the developmental programming of offspring phenotype 38 
by suboptimal intrauterine growth. 39 
 40 
KEY POINTS SUMMARY 41 
 42 
• Size at birth is critical in determining life expectancy and is dependent primarily on the placental 43 
supply of maternal nutrients and oxygen. 44 
• The insulin-like growth factors (IGFs) are important in controlling placental resource allocation to 45 
fetal growth during development via their impacts on placental morphogenesis, substrate 46 
transport and hormone secretion. 47 
• Placental IGFs (particularly IGF2) alter in response to environmental challenges known to affect 48 
placental phenotype and fetal growth. 49 
• IGFs have an important role in optimising fetal growth with respect to resource availability 50 
during pregnancy via actions on placental phenotype. 51 
 52 
 53 
 54 
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 65 
INTRODUCTION  66 
Intrauterine growth is a key determinant of lifespan. Babies born growth restricted or large for 67 
gestational age are at greater risk of perinatal morbidity and mortality than those of normal birth 68 
weight. Moreover, the “memories” of an altered environment and growth in utero can stretch 69 
beyond the perinatal period to influence health much later in life. Epidemiological studies in humans 70 
have shown that babies grown abnormally due to poor maternal nutrition are at heightened risk of 71 
developing conditions like type 2 diabetes, heart disease and obesity as adults, and of dying younger 72 
as a consequence (Gluckman et al., 2005; Jansson & Powell, 2006). Similarly, manipulating 73 
intrauterine growth experimentally by varying maternal food intake, dietary composition, oxygen 74 
availability, endocrine status or utero-placental blood flow has been shown to program 75 
cardiovascular, metabolic and endocrine function of the adult offspring in a wide range of 76 
mammalian species (Gluckman et al., 2005; McMillen & Robinson, 2005; Fowden et al., 2006).  77 
 78 
As the interface between the mother and fetus, the placenta is one of the main determinants of 79 
intrauterine growth. It supplies all the nutrients and oxygen required for fetal growth as well as 80 
secreting hormones that influence maternal metabolism in favour of the fetal needs. Its 81 
morphological and functional characteristics, therefore, have an important role in determining the 82 
allocation of maternal resources to fetal growth. These characteristics include cell composition, 83 
surface area, barrier thickness, blood flow, vascularity, nutrient utilisation and the abundance and 84 
activity of the various transporter molecules (Fowden et al., 2009; Sandovici et al., 2012).  Recent 85 
studies have shown that the placenta can respond to maternal nutritional and metabolic signals by 86 
altering these characteristics which, in turn, leads to changes in the placental capacity to supply 87 
resources to the fetus (Fowden et al., 2009; Sandovici et al., 2012). Thus, the placenta is a key 88 
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mediator in linking maternal environmental conditions to development of the fetus (Burton et al., 89 
2016; Sferruzzi-Perri & Camm, 2016). However, the molecular mechanisms by which the placenta 90 
senses and responds to environmental cues during pregnancy are poorly understood. This review 91 
discusses the role of the insulin-like growth factors (IGFs) in controlling placental resource allocation 92 
to intrauterine growth, particularly in relation to maternal environmental conditions during 93 
pregnancy. It focuses primarily on small laboratory animals, like mice, rats and guinea pigs that are 94 
most commonly used for these studies but also draws on data from other species, including humans, 95 
where available. 96 
 97 
 98 
THE INSULIN-LIKE GROWTH FACTORS 99 
 100 
The insulin-like growth factors (IGFs), IGF1 and IGF2, are 7.5kDa single-chained polypeptides that 101 
promote growth, both before and after birth. They affect the metabolism, mitogenesis, survival and 102 
differentiation of a wide variety of cell types by binding to IGF receptors (IGF1R and IGF2R), insulin 103 
receptor (INSR) and a hybrid IGF1R-INSR receptor with varying affinity (Sferruzzi-Perri et al., 2008; 104 
Fernandez & Torres-Aleman, 2012; Harris & Westwood, 2012). Their actions are influenced by at 105 
least six different IGF binding proteins (IGFBP-1 to IGFBP-6) and numerous IGF-related binding 106 
proteins, which alter access of the IGFs to their receptors and have been reviewed in detail 107 
elsewhere (Bach et al., 2005; Bach, 2015; Clemmons, 2016). The main signalling receptor for the IGFs 108 
is IGF1R, which activates the phosphoinositide-3 kinase/protein kinase A (PI3K/AKT) and mitogen-109 
activated protein kinase (MAPK) signalling pathways. IGF2 also binds to the IGF2R, which can lead to 110 
either IGF2 degradation or activation of the G-protein-coupled signalling pathway (Okamoto et al., 111 
1990).  112 
 113 
The Igf2 gene is subject to parental imprinting and only the paternal allele is expressed. It can be 114 
expressed by different promoters, of which P0 (Igf2P0) is specific to the placenta in mice (Moore et 115 
al., 1997). In mice, though largely not in humans, the Igf2r gene is also imprinted but in a reciprocal 116 
fashion to Igf2 with expression from the maternal allele (Monk et al., 2006). The IGFs (particularly 117 
IGF2), their receptors and signalling pathways are expressed by the placenta in many species and 118 
change in their abundance both developmentally and in response to environmental cues (Sferruzzi-119 
Perri et al., 2010). In many species, circulating IGF concentrations are higher during pregnancy than 120 
in the non-pregnant animal and also change in the mother and fetus with proximity to delivery 121 
(Fowden, 2003; Sferruzzi-Perri et al., 2010).  IGF2 is more abundant than IGF1 in both the maternal 122 
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and fetal circulations in all species studied to date, with the exception of mice (Fowden, 2003; 123 
Sferruzzi-Perri et al., 2010). IGF2 is also more highly expressed than IGF1 by the placenta in all 124 
species studied to date (Sferruzzi-Perri et al., 2010).  125 
 126 
 127 
THE EFFECTS OF THE INSULIN-LIKE GROWTH FACTORS ON PLACENTAL PHENOTYPE  128 
 129 
The effects of the IGFs on the placenta have been studied directly in two main ways. First, they have 130 
been given exogenously either to placental cultures in vitro or to pregnant animals in vivo to study 131 
placental growth, transport and endocrine function. Secondly, the Igf genes, their receptors and key 132 
molecules in their downstream pathways have been under- or over-expressed in genetically 133 
modified mice to determine the morphological and functional consequences for the placenta at 134 
different stages of pregnancy. While the functions of the placenta are common across species, its 135 
structure varies in terms of shape, organisation of trophoblast lineages, extent of invasion into the 136 
maternal uterus, and degree of interdigitation at the feto-materno interface (reviewed in depth 137 
elsewhere (Carter, 2007; Wooding & Burton, 2008; Roberts et al., 2016)). For instance, the human 138 
and non-human primate placenta is composed of a series of highly branched structures, called villi. 139 
These contain a mesenchymal core that has fetal capillaries which are closely associated with an 140 
overlying syncytiotrophoblast layer. The syncytiotrophoblast is directly bathed in maternal blood and 141 
functions in both transport and hormone secretion. Cytotrophoblast cells, can fuse to form the 142 
syncytiotrophoblast or migrate from the villous tree into the decidua where they invade and 143 
remodel uterine spiral arteries to promote blood flow to the placenta. The syncytiotrophoblast is 144 
also bathed in maternal blood in the mouse, rat and guinea pig placenta. However, the mouse 145 
placenta is arranged into two morphologically and functionally distinct regions; the labyrinth zone 146 
(Lz) that is responsible primarily for transport and the junctional zone (Jz; also known as basal or 147 
interlobium region) which functions in uterine remodelling/invasion and hormone secretion. In 148 
ruminate species like the sheep and cow the placenta is comprised of individual placentomes which 149 
form at specialised sites called caruncles, in the uterine wall. The overlaying trophoblast layer can be 150 
a syncitium (in sheep) or remains uni-cellular (columnar epithelium; in cows) and there no invasion 151 
of the maternal blood vessels by trophoblast cells. However, in sheep some trophoblast cells migrate 152 
and fuse with caruncle epithelial cells and play an endocrine role.   153 
 154 
 155 
 156 
Exogenous administration of IGFs  157 
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In vitro experiments 158 
IGF1 and IGF2 prevent apoptosis and enhance proliferation and migration/invasion of human 159 
placental villous explants, primary trophoblast cultures and trophoblast cell lines from the first 160 
trimester and term (Table 1). IGF1 also promotes the proliferation, invasion and survival of first 161 
trimester human placental fibroblasts (Miller et al., 2005) and the differentiation of term trophoblast 162 
cells into syncytiotrophoblast (Bhaumick et al., 1992; Milio et al., 1994; Cohran et al., 1996). 163 
Similarly, IGF1 stimulates proliferation and migration of murine ectoplacental cone trophoblast in 164 
culture (Kanai-Azuma et al., 1993) and early pregnancy porcine trophoblast cells (Jeong et al., 2014). 165 
Furthermore, IGF2 promotes differentiation of murine ectoplacental cone trophoblast and migration 166 
of ovine trophoblast cells in vitro (Kim et al., 2008). Using receptor and pathway inhibitors and IGF 167 
analogues with selectivity for particular receptors, some of the molecular mechanisms mediating the 168 
actions of IGFs on the human placenta have begun to be identified in vitro. IGFs appear to mediate 169 
their proliferative and anti-apoptotic effects on trophoblast through activating IGF1R and triggering 170 
the MAPK and PI3K/AKT signalling pathways, respectively (Forbes et al., 2008). IGFs also induce 171 
trophoblast migration and invasion through IGF1R, and possibly INSR with subsequent activation of 172 
MAPK and PI3K/AKT signalling pathways (Diaz et al., 2007; Shields et al., 2007; Forbes et al., 2008; 173 
Mayama et al., 2013). However, IGF2 may also signal via IGF2R and Gi proteins, MAPK and Rho 174 
GTPase pathways to trigger trophoblast migration and invasion (McKinnon et al., 2001; Shields et al., 175 
2007; Harris et al., 2011). Thus IGFs promote the growth of different cell lineages in the placenta via 176 
multiple mechanisms (Figure 1A). 177 
 178 
In addition to stimulating placental growth, both IGFs stimulate glucose and System A amino acid 179 
uptake and IGF1 increases System L activity but reduces lipoprotein lipase activity in human 180 
trophoblast in vitro (Table 1). However, these changes in nutrient uptake do not always track with 181 
the expression of the transporter genes or proteins, suggesting that the IGFs may also affect post-182 
transcriptional/translational mechanisms (Fang et al., 2006; Jones et al., 2013; Jones et al., 2014). 183 
Indeed, IGF1 was recently shown to stimulate glucose transporter capacity by increasing the 184 
translocation of GLUT1/SLC2A1 to the trophoblast plasma membrane (Baumann et al., 2014). In 185 
culture, IGF1 prevents the release of the vaso-constrictors, prostaglandin E and F, and thromboxane, 186 
by the term human placenta and reduces the agonist-mediated vasoconstriction of human 187 
myometrial arteries (Siler-Khodr et al., 1995; Corcoran et al., 2012). In vivo, these effects could 188 
increase utero-placental blood flow and substrate transfer in late gestation. Both IGF1 and IGF2 also 189 
enhance trophoblast endocrine capacity in culture. IGFs increase the secretion of hormones 190 
including progesterone, human chorionic gonadotrophin and placental lactogen in vitro although 191 
7 
 
others, like placental growth hormone may not be affected (Maruo et al., 1995; Zeck et al., 2008; 192 
Rak-Mardyla & Gregoraszczuk, 2010). In addition, IGF2 simulates the differentiation of hormone-193 
producing murine and ovine trophoblast in vitro (Kanai-Azuma et al., 1993; Kim et al., 2008). Thus, 194 
IGFs have the capacity to promote growth, hormone secretion and substrate transport capacity of 195 
the placenta. 196 
 197 
 198 
In vivo experiments 199 
Treatment of guinea pig dams with either IGF1 or IGF2 in early-mid pregnancy increases fetal weight 200 
near term [Table 1; (Sferruzzi-Perri et al., 2006)]. With exogenous IGF1, placental Lz area and Igf2 201 
gene expression is reduced during the treatment, even though fetal weight is increased already in 202 
mid pregnancy (Sohlstrom et al., 2001; Sferruzzi-Perri et al., 2007b; Standen et al., 2015). Whilst 203 
there is no sustained effect of either IGF on placental weight, IGF2 increases the volume and surface 204 
area of the transport Lz, near term [Table 1, (Sferruzzi-Perri et al., 2006)]. Development of the 205 
placental exchange region was further enhanced when the IGF2R-selective synthetic analogue, 206 
Leu27-IGF2 was administered maternally (Sferruzzi-Perri et al., 2008). In mice, maternal Leu27-IGF2 207 
treatment from day 13 of pregnancy halves the number of fetuses naturally growth-restricted within 208 
the litter near term (Charnock et al., 2016). Taken together, these findings suggest that maternal 209 
IGF2 in early gestation may act, in part, via the IGF2R to enhance functional development of the 210 
placenta with beneficial impacts on fetal growth. However, caution is warranted as part of the 211 
effects of Leu27-IGF2 could be due to the displacement of endogenous IGF2 and its subsequent 212 
interaction with IGF1R and INSR in the placenta.  213 
 214 
Exogenous IGFs also modify the functional capacity of the placenta to supply resources for fetal 215 
growth. In the late pregnant ewe, increasing IGF1 in the fetal circulation increases amino acid and 216 
glucose uptake by the placenta but may reduce materno-fetal transfer of these substrates, lactate 217 
production and the number of placentomes (Table 1). Increasing IGF1 in the maternal circulation 218 
also alters placental metabolic function in the pregnant ewe near term; glucose transfer capacity 219 
and lactate production are enhanced by an acute infusion of IGF1 (Liu et al., 1994). In guinea pigs, 220 
placental delivery of glucose and/or neutral amino acids to the fetus is increased in late gestation by 221 
chronic maternal IGF treatment in early-mid pregnancy (Table 1). This enhanced placental transfer in 222 
late gestation is partly due to increased expression of nutrient transporters (System A amino acid; 223 
SNAT2/Slc38a2) by IGF1 in mid pregnancy and improved development of the exchange region by 224 
IGF2 in late pregnancy (Sferruzzi-Perri et al., 2006; Sferruzzi-Perri et al., 2007b). In mice, the 225 
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variability in System A amino acid transport capacity and conceptus weight within the litter is 226 
abolished by maternal Leu27-IGF2 (Charnock et al., 2016) and data suggest that IGFs may have most 227 
benefit for improving growth of the smallest pups. Indeed, maternal Leu27-IGF2 improves the weight 228 
of fetuses that are growth restricted due to a lack of the endothelial nitric oxide gene and reduces 229 
the number of pups below the fifth centile of the wild-type population in late gestation (Charnock et 230 
al., 2016). In addition to improving placental transport function, exogenous IGFs also affect 231 
endocrine capacity in vivo (Figure 1B). Maternal IGF2 treatment simulates the development of the 232 
endocrine Jz of the rat placenta (Van Mieghem et al., 2009) and exogenous IGF1 and IGF2 increase 233 
placental pro-renin activation in guinea pigs (Standen et al., 2015). Thus, IGFs may also increase fetal 234 
resource supply through changing placental endocrine function and thus maternal adaptations to 235 
pregnancy, however further studies are warranted. 236 
 237 
To circumvent possible confounding effects of systemic IGF treatment on the mother, approaches 238 
are being developed to target IGFs to the placenta. In mice, adenoviral-mediated site-specific 239 
intraplacental transfer of the Igf1 gene on day 14 of pregnancy, increases the area of the placenta, 240 
the size of the Lz and of the maternal and fetal facing areas three days later, although there is no 241 
change in conceptus weight [Table 1; (Katz et al., 2009)]. In response to liposome-mediated targeting 242 
of IGF2 to the mouse placenta, placental growth is also increased although fetal weight is not 243 
affected (King et al., 2016). In rabbits, the weight of natural runt fetuses in the litter is increased two 244 
days following placental Igf1 transgene delivery without a change in placental weight however how 245 
it impacts on structure and function of the placenta remains unknown (Keswani et al., 2015). These 246 
data suggest that targeting of IGF delivery to the placenta may prove an effective method of 247 
improving placental function and, thus, fetal growth, particularly when feto-placental growth is 248 
impaired. 249 
 250 
 251 
Genetic manipulation of the IGF system  252 
In mice, knockout of the Igf2 gene in the entire conceptus or predominantly within the fetal or 253 
trophoblast cell lineages leads to placental and fetal growth restriction, with the greatest reduction 254 
in growth seen with ubiquitous Igf2 loss (Table 2). Similarly, a heterozygous deficiency in the PI3K-255 
p110α (Pik3ca; homozygous deficiency is lethal) or complete ablation of the AKT1 (Pkba) or MAPK1 256 
(Erk2) genes, causes feto-placental growth restriction (Cho et al., 2001; Hatano et al., 2003; Yang et 257 
al., 2003; Yung et al., 2008; Kent et al., 2012; Sferruzzi-Perri et al., 2016). In contrast, over-expressing 258 
the Igf2 gene through activating the normally silent maternal gene copy in the H19 null, increasing 259 
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IGF2 availability via Igf2r ablation, or deletion of the PI3K signalling inhibitor (Pten), results in over-260 
growth of the fetus and placenta (Leighton et al., 1995; Ludwig et al., 1996; Louvi et al., 1997; 261 
Ripoche et al., 1997; Church et al., 2012). Deletion of the Igf1, Igf1r or Insr genes in mice also leads 262 
to fetal growth restriction, but placental weight is unaffected (DeChiara et al., 1990; Baker et al., 263 
1993; Louvi et al., 1997). This suggests that the growth-promoting effect of IGF2 in the mouse 264 
placenta occurs independently of IGF1R and INSR, possibly through an unknown, distinct placental-265 
specific receptor (XRp) (Louvi et al., 1997). However, evidence from H19 null mutants suggests that 266 
IGF1R could contribute to the control of placental growth in mice as the first exon of the H19 gene 267 
encodes miR-675 which targets Igf1r for reduced expression (Keniry et al., 2012). Overgrowth of the 268 
H19 null placenta (Leighton et al., 1995; Esquiliano et al., 2009; Angiolini et al., 2011; Church et al., 269 
2012), is thus thought to be due to biallelic Igf2 via imprinting mechanisms, as well as, enhanced 270 
Igf1r expression through loss of miR-675 (Keniry et al., 2012). Taken together, these data highlight 271 
the importance and complexity of the IGF system in controlling conceptus growth in mice. 272 
 273 
Genetic manipulations of Igf2, Igf2r and the downstream signalling pathways also affect the 274 
morphology of the placenta (Table 2). For instance, loss of Igf2 (complete and Igf2P0 null), Pik3ca, 275 
Pkba or Erk2 gene expression causes defective Lz formation. In particular, Lz volume/thickness, 276 
exchange surface area and vascularisation are all reduced and the interhaemal barrier to diffusion of 277 
gases like oxygen is greater in the placenta of all these mutants (Table 2). In contrast, in the H19 null, 278 
the Lz surface area is increased in line with the placentomegally observed (Angiolini et al., 2011). In 279 
addition, IGF2 affects the formation of endocrine cells in the placenta. In particular, loss or gain of 280 
Igf2 or the PI3K-AKT signalling pathway causes a disproportionate decrease or expansion of the 281 
glycogen cells in the Jz, whereas Igf1r or Insr nulls show no changes in Jz glycogen cell abundance 282 
(Table 2).  Collectively, the available data suggest that IGF2 acts via both the PI3K/AKT and MAPK 283 
pathways to attain normal placental weight and Lz structure, and through PI3K/AKT signalling to 284 
drive placental glycogen cell formation in mice (Figure 2A).  285 
 286 
Placental function also changes when the IGF system is genetically modified in mice (Table 2). The 287 
passive permeability of the placenta to hydrophilic nutrients/solutes is reduced in the complete Igf2 288 
null, placental-specific Igf2P0 null and H19 null (Constancia et al., 2002; Sibley et al., 2004; Coan et 289 
al., 2008b; Angiolini et al., 2011). The complete Igf2 null placenta transports less neutral amino acid 290 
(methyl amino-isobutyric acid, MeAIB) via the System A transporters in association with reduced 291 
SNAT2/Slc38a2 expression (Constancia et al., 2005). There is also reduced abundance of System XAG- 292 
and System Y+ transporters, responsible for placental transfer of cationic and anionic amino acids, in 293 
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the complete Igf2 and the Igf1r null (Matthews et al., 1999). In contrast, the Igf2P0 null placenta 294 
transports more neutral amino acids via System A, as well as, more glucose and calcium in late 295 
gestation (Table 2). Up-regulation of placental transport capacity is associated with increased 296 
expression of SNAT4/Slc38a4 and GLUT3/Slc2a3 by the Igf2P0 deficient placenta. In contrast to Igf2, 297 
there is little or no information on the capacity of the Igf1 or Insr null placenta to supply nutrients to 298 
the fetus. In the complete Igf2 null, placental and fetal growth restriction occurs concurrently and 299 
becomes evident in mid-gestation [Table 2; (Baker et al., 1993; Constancia et al., 2005)]. In the 300 
Igf2P0 null, placental weight is reduced at a similar time in gestation, but fetal growth only becomes 301 
restricted much closer to term and to a lesser extent than in the complete Igf2 null (Baker et al., 302 
1993; Constancia et al., 2002; Constancia et al., 2005). Liposome-mediated targeting of IGF2 to the 303 
placenta has recently been shown to increase the weight of Igf2P0 null mouse fetuses near term 304 
[Table 1; (King et al., 2016)]. Collectively, these findings suggest that the Igf2P0 null placenta 305 
compensates for its defective development and compromised permeability by adaptively up-306 
regulating its nutrient transport systems and thereby, minimises the degree of fetal growth 307 
restriction, relative to the complete Igf2 null. The Pik3ca heterozygote deficient placenta also 308 
transfers glucose and amino acids via System A transporters with increased efficiency in 309 
compensation for its impaired development, which is associated a less severe reduction in fetal 310 
weight close to term than earlier in gestation (Sferruzzi-Perri et al., 2016). Moreover, the naturally 311 
small placenta that supports more fetal mass per gram shows increased expression of Igf2P0 312 
coupled with a preservation of Lz growth and with increased placental System A transport capacity 313 
and SNAT2/Slc38a2 abundance compared to the large placenta in the litter (Coan et al., 2008a). In 314 
contrast, the over-grown H19 null placenta shows diminished neutral amino acid and glucose 315 
transport which is thought to limit fetal over-growth and avoid an excessive drain of maternal 316 
resources into the fetus (Angiolini et al., 2011). Thus, IGF2 in the placenta is important for fine-317 
tuning nutrient supply to the fetus (Figure 2B). 318 
 319 
In addition to effects on placental transport, the Igf2 gene may also affect the endocrine function of 320 
the placenta with consequences for maternal physiology during pregnancy. Evidence for this stems 321 
from associations between altered placental Jz formation in H19 and Igf2P0 null mutants  and raised 322 
circulating glucose, insulin and/or corticosterone in phenotypically wild-type dams (Petry et al., 323 
2010; Sferruzzi-Perri et al., 2011). Thus, IGF2 has an important role in nutrient allocation to the 324 
fetus.  By regulating placental phenotype, it balances the fetal genetic drive for growth with the 325 
maternal ability to supply the required resources, thereby optimising both offspring and maternal 326 
fitness. 327 
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 328 
 329 
IGFS AS ENVIRONMENTAL SIGNALS IN REGULATING PLACENTAL RESOURCE ALLOCATION TO FETAL 330 
GROWTH 331 
 332 
IGFs may also play an important role in changing placental resource allocation to the fetus in 333 
environmentally-challenged pregnancies. As Igf1 expression is relatively low in the placenta, studies 334 
have largely focussed on placental expression of Igf2 and activation of its signalling pathways (Table 335 
3). However, since the signalling pathways are responsive to both IGFs, the placenta can also 336 
respond to changes in circulating IGF1 and IGF2 induced by nutritional or other environmental cues.  337 
 338 
 339 
Maternal nutrition 340 
Undernutrition  341 
In mice, guinea pigs and baboons, undernutrition restricts placental growth in association with a 342 
decrease in the expression of Igf2 and/or signalling via the PI3K/AKT and MAPK pathways (Table 3). 343 
There are also reductions in placental vascularisation, exchange surface area, Jz volume and 344 
glycogen cell abundance and/or a greater barrier to diffusion with maternal undernutrition in mice 345 
and guinea pigs; morphological parameters that were altered similarly by a genetic deficiency in Igf2, 346 
Pik3ca, Pkb and Erk2 (Tables 2 and 3). Together, these studies suggest that decreases in IGF2 347 
expression and signalling within the placenta could underlie the growth and morphological defects 348 
observed with maternal undernutrition in these species. In larger animals, the expression of Igf2 and 349 
its signalling machinery reduces, is unchanged or even increases in response to undernutrition (Table 350 
3). For instance, signalling via MAPK and PI3K/AKT in the placenta is up-regulated in nutrient-351 
restricted ewes and hiefers (Zhu et al., 2007a; Zhu et al., 2007b; Ma et al., 2011). In these models, 352 
changes in signalling relate to a normalisation of placental weight or an increase in placental 353 
cotyledon vascularity. They also correlate with a maintenance or restoration of fetal weight in later 354 
gestation, despite an exposure to undernutrition. In ewes of a moderate condition, which have the 355 
smallest placentas supporting more mass of fetus per gram, placental expression of Igf2 is greatest 356 
(Osgerby et al., 2003). These studies therefore suggest that in larger species, there is morphological 357 
adaptation of the placental to an adverse maternal nutritional state through increasing Igf2 and 358 
growth signalling locally.  359 
 360 
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In the undernourished sheep placenta with increased PI3K/AKT and MAPK signalling, the expression 361 
of glucose and fatty acid transporters is also increased (Ma et al., 2011). However, in 362 
undernourished baboons, diminished Igf2 expression and signalling in the placenta accompanies 363 
reductions in Systems A and L amino acid transporter capacity and glucose transporter gene 364 
expression (Pantham et al., 2015; Pantham et al., 2016). Taken together, these studies suggest that 365 
IGF2 and the PI3K/AKT and MAPK signalling pathways could also mediate changes in placental 366 
transport function during undernutrition. In mice, despite a 20% reduction in maternal food intake 367 
and placental growth restriction earlier in gestation, fetal weight is normal until just prior to term 368 
(Coan et al., 2010). This maintenance of fetal growth relates to an initial preservation of Lz 369 
development in earlier gestation and an adaptive up-regulation of System A amino acid transporter 370 
capacity and SNAT2/Slc38a2 expression near term, by the growth restricted undernourished 371 
placenta. However, in mice lacking the placental-specific Igf2 isoform (Igf2P0) these adaptations to 372 
maternal undernutrition fail to occur. The development of the placental exchange region is 373 
compromised earlier in gestation, there is no up-regulation of amino acid transport or 374 
SNAT2/Slc38a2 expression and reduced SNAT4/Slc38a4 abundance near term in Igf2P0 null 375 
placentas compared to wildtype in undernourished mice (Sferruzzi-Perri et al., 2011). As a result, 376 
fetal growth is restricted earlier in gestation and more adversely affected near term by 377 
undernutrition, in Igf2P0 nulls. The Igf2P0 transcript is, therefore, a major determinant of the 378 
environmental modification of placental phenotype with undernutrition in mice. The expression of 379 
genes involved in glucose, neutral amino acid and fatty acid transport, as well as, the IGF signalling 380 
pathways in the human placenta are modified by the diet and physical activity of the mother during 381 
pregnancy (Brett et al., 2015). Thus, the IGF system may also be important for modifying resource 382 
capacity of the human placenta in response to changes in the maternal environment.  383 
 384 
 385 
Low-protein diets 386 
During rodent pregnancy, consumption of an iso-calorific low protein diet has inconsistent impacts 387 
on both placental weight and placental Igf2 expression [Table 3 and (Sferruzzi-Perri & Camm, 2016)]. 388 
However, the nature of the specific effect appears to depend on the degree of protein deprivation, 389 
stage of pregnancy studied and sex of the conceptus (Jansson et al., 2006; Coan et al., 2011; Nusken 390 
et al., 2011; Gao et al., 2012a). Despite the contrasting results, placental Igf2 expression seems to 391 
track positively with the weight of the placenta in mice and rats (Coan et al., 2011; Nusken et al., 392 
2011; Gao et al., 2012a). For instance, in pregnant mice, low protein diets cause placentomegaly and 393 
the degree of placental weight increase relates to the level of Igf2 up-regulation at first appearance 394 
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of growth enhancement (Coan et al., 2011). The variation in placental growth and Igf2 expression 395 
observed in different models of protein deficiency could be caused by the content and source of 396 
carbohydrate used to maintain calorie intake. Nevertheless, taken together, these findings suggest 397 
that at least part of the changes in placental growth seen with protein deprivation could be 398 
mediated through local changes in Igf2.  399 
 400 
There are also changes in placental transport capacity with gestational protein malnutrition. For 401 
instance, in response to a diet with 8% protein, the mouse placenta adaptively transports more 402 
glucose to the fetus on day 16 of pregnancy (Coan et al., 2011). This up-regulation occurs when 403 
placental Igf2 expression is also increased and when fetal growth is maintained despite maternal 404 
protein deprivation (Coan et al., 2011). A few days later however, glucose transport is unchanged, 405 
System A amino acid transporter abundance is reduced and Igf2 expression no longer increased in 406 
the placenta by a low protein diet, and fetal growth restriction ensues (Coan et al., 2011). These data 407 
suggest that placental Igf2 may be important for adapting nutrient supply to the fetus in response to 408 
maternal protein malnutrition in mice. However, there is evidence that pathways downstream of 409 
Igf2 may also be important. For instance, the mechanistic target of rapamycin (mTORC1) mediates 410 
the mitogenic and metabolic actions of IGFs (Jansson et al., 2012b). In rats, protein deprivation 411 
reduces mTORC1 signalling, Systems A and L amino acid transport and SNAT2/Slc38a2, LAT1/Slc7a5 412 
and LAT2/ Slc7a8 expression by the placenta, prior to the appearance of placental and fetal growth 413 
restriction (Jansson et al., 2006; Rosario et al., 2011). These findings suggest that down-regulation of 414 
signalling pathways like mTORC1 and amino acid transporters in the placenta could link maternal 415 
protein restriction to decreases in fetal growth. The availability of protein and specific amino acids 416 
during pre-implantation rodent development is linked to alterations in the expression of genes 417 
within the H19-Igf2 locus, mTORC1 signalling and trophoblast cell formation and differentiation with 418 
consequences for feto-placental phenotype in late gestation (Kwong et al., 2006; Van Winkle et al., 419 
2006; Eckert et al., 2012; Watkins et al., 2015). Thus, changes in Igf2 expression and its signalling 420 
pathways could be responsive to the availability of nutrients from the earliest stages of 421 
development. 422 
 423 
 424 
Diets with excess sugar and/or fat  425 
The expression of Igf2 and its signalling pathways in the placenta are inconsistently altered by diets 426 
with excess sugar and/or fat (Table 3). Weight of the conceptus may also be reduced, increased or 427 
unchanged, depending on the level of fat in the diet, the amount of simple sugars consumed and the 428 
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timing of the dietary manipulation [Table 3 and reviewed in (Sferruzzi-Perri & Camm, 2016)]. Part of 429 
these variations in Igf2 expression and conceptus growth could be due to the differences in protein 430 
and micronutrient intake, as species like mice and rats control their calorie intake tightly (Keesey & 431 
Hirvonen, 1997). In mice fed a diet containing 2.5-times the fat of the controls, placental weight is 432 
reduced in early pregnancy in association with decreases in the expression of Igf2 and signalling 433 
machinery, including Mtor (Sasson et al., 2015). These placental changes accompanied reductions in 434 
the expression of System A amino acid transporter, SNAT1/Slc38a1, glucose transporter 435 
GLUT1/Slc2a1 and/or fatty acid translocase, CD36 depending on the length of high fat feeding and 436 
whether the diet was eaten before pregnancy (Sasson et al., 2015). In over-nourished ewes, 437 
placental weight is reduced in mid-gestation in association with decreased activity of the IGF 438 
signalling pathway (including activation of IRS1 and mTORC1) and changes in vessel size and density 439 
in the placenta (Zhu et al., 2009; Ma et al., 2010). However, fetal weight is increased along with fatty 440 
acid transporters and translocases in the placenta, suggesting that alternative signalling pathways 441 
may be activated to adapt placental nutrient supply to the fetus in ewes with excess food intake 442 
(Zhu et al., 2010; Tuersunjiang et al., 2013). 443 
 444 
In other studies, increases in the placental IGF system are coupled with improved placental resource 445 
allocation to the fetus in dams fed obesogenic diets (King et al., 2013; Sferruzzi-Perri et al., 2013; 446 
Diaz et al., 2015; Rosario et al., 2015; Rosario et al., 2016). For instance, in mice, consumption of a 447 
high sugar and fat diet from day 1 of pregnancy initially causes conceptus growth restriction and 448 
morphological defects in the placental Lz. However, fetal weight normalises by term, despite the 449 
persistence of placental growth and morphological defects through adaptive up-regulation of 450 
glucose and neutral amino acid transport to the fetus by the placenta (Sferruzzi-Perri et al., 2013). 451 
Up-regulation of transport capacity relates to increased expression of GLUT3/Slc2a3 and 452 
SNAT2/Slc38a2, as well as, elevated expression of the placental-specific Igf2 isoform and PI3K/AKT 453 
signalling in the placenta in dams fed a diet with excess sugar and fat. Obesogenic diets fed from 454 
before pregnancy also increase placental nutrient transporter capacity (glucose, Systems A and L 455 
amino acid and fatty acids) in line with greater Igf2 or PI3K/AKT and mTORC1 signalling, however 456 
responses varied with the precise composition of the diet and possibly, fetal sex (King et al., 2013; 457 
Aye et al., 2015; Diaz et al., 2015; Rosario et al., 2015; Rosario et al., 2016). The expression of IGF 458 
signalling machinery (receptors, AKT, mTORC1) and nutrient transporters is also altered in the 459 
placenta from obese women, however, the specific nature of these changes appears to depend on 460 
the level of maternal body fat mass, gestational weight gain and whether macrosomia is observed 461 
(Jansson et al., 2012a; Brett et al., 2016; Martino et al., 2016). Taken together, these findings suggest 462 
15 
 
that obesity and obesogenic diets alter placental phenotype in association with changes in placental 463 
Igf2 system and fetal growth.  464 
 465 
 466 
Maternal hypoxia 467 
In mice, hypoxia typically reduces fetal growth in a severity-dependent manner without a change in 468 
placental weight [Table 3 and reviewed in (Sferruzzi-Perri & Camm, 2016)]. However, if the hypoxic 469 
challenge commences early in pregnancy, placentomegaly is observed in associated with greater 470 
maternal blood spaces and activation of the PI3K/AKT and mTORC1 signalling pathways in the 471 
placenta (Matheson et al., 2015). Even though placental weight may not be altered when maternal 472 
hypoxia commenced later in pregnancy, placental expression of the IGF system and capacity to 473 
supply resources to the fetus is altered (Table 3). In particular, placental expression of IGF receptors, 474 
INSR and PI3K isoforms is decreased in response to five days of 13%-10% maternal hypoxia in late 475 
mouse gestation, and in 10% hypoxia this effect is due to reductions in maternal food intake (Cuffe 476 
et al., 2014; Higgins et al., 2015). However, expression of Igf2, Igf2P0 and activated AKT increases 477 
with 13% hypoxia, but is unchanged or even decreased in response to 5 days of 12-10% hypoxia near 478 
term (Cuffe et al., 2014; Higgins et al., 2015). In the 13% hypoxic mouse placenta showing increases 479 
in IGF2 expression and signalling, there are beneficial changes in Lz structure including improved 480 
vascularisation, maternal blood spaces and a thinner diffusion barrier to exchange; changes that 481 
would optimise oxygen delivery to the fetus near term (Higgins et al., 2015; Matheson et al., 2015). 482 
There is also greater placental glucose uptake and transport and maintained delivery of neutral 483 
amino acids to the fetus when 13% hypoxia occurs in the last third of pregnancy (Higgins et al., 484 
2015). In contrast, in the 12-10% hypoxic placenta with unchanged or decreased expression of the 485 
IGF2 system, the morphology of the placental Lz is compromised, with reductions in maternal blood 486 
spaces and surface area and a greater barrier to diffusion; changes that would further limit fetal 487 
oxygen supply in hypoxic dams (Cuffe et al., 2014; Higgins et al., 2015). Moreover, placental glucose 488 
uptake and transport capacity is not up-regulated or even reduced (less GLUT1/Slc2a1) and delivery 489 
of neutral amino acids diminished, in dams exposed to 12-10% hypoxia, depending on whether food 490 
intake is reduced and the sex of the fetus (Cuffe et al., 2014; Higgins et al., 2015). In culture, 1% 491 
hypoxia reduces the outgrowth of mouse ectoplacental cone trophoblast in association with 492 
diminished Igf2 expression (Pringle et al., 2007). Hypoxia (1% oxygen) also diminishes the expression 493 
of PI3K/AKT and mTORC1 signalling in human trophoblast cell lines (Yung et al., 2012a) and 494 
modulates IGF1 and IGF2 signalling in early pregnancy placental mesenchymal stem cells (Youssef et 495 
al., 2014; Youssef & Han, 2016). Placental expression of the PI3K/AKT and mTORC1 signalling 496 
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pathways and GLUT1/Slc2a1 expression are decreased in women at 3100m above sea level who 497 
deliver growth-restricted babies (Zamudio et al., 2006; Yung et al., 2012a). In addition, inducing 498 
endoplasmic stress in the mouse placental Jz genetically is associated with defects in PI3K/AKT and 499 
mTORC1 signalling, altered IGF2 glycosylation and bioactivity, and with feto-placental growth 500 
restriction (Yung et al., 2012b). Taken together, these findings suggest that activating IGF2 and/or 501 
PI3K/AKT signalling in the placenta may be critical for adapting placental resource allocation to the 502 
fetus during hypoxia in late pregnancy. They also suggest that the placenta may integrate signals of 503 
oxygen and nutrient availability through the IGF2 system to adapt its phenotype and optimize 504 
maternal resource supply to fetal growth. Indeed, the mouse Igf2 gene harbours a hypoxia-505 
responsive element in its promoter (Feldser et al., 1999), as well as CHORE motifs, which bind the 506 
glucose-responsive transcription factor, MLX (Hunt et al., 2015). Therefore, the availability of oxygen 507 
and nutrients in utero could have direct effects on placental Igf2. Nutritional and hypoxic challenges 508 
alter the concentration of hormones like the glucocorticoid stress hormone and insulin, in the 509 
maternal circulation (Sferruzzi-Perri et al., 2011; Cuffe et al., 2014). Thus, changes in placental 510 
phenotype may reflect alterations in the metabolic and endocrine state of the mother.  511 
 512 
Maternal endocrine challenges 513 
Endocrine challenges can affect maternal metabolism and utilisation of nutrients and thus the 514 
partitioning of resource to the conceptus in pregnancy (Vaughan et al., 2011). Administering 515 
corticosterone or the synthetic glucocorticoid, dexamethasone to rodents for 3-7 days reduces fetal 516 
and placental weights during gestation [Table 3 and (Vaughan et al., 2011)].  In mice, corticosterone 517 
decreases AKT and mTORC1 activation in association with reductions in feto-placental weight, Lz 518 
vascularisation and glucose and System A amino acid transporter capacity, however the specific 519 
nature of these effects depend on when in pregnancy the over-exposure occurs (Table 3). 520 
Administering the synthetic glucocorticoid, dexamethasone reduces the expression of MAPK and 521 
weight of placenta in female, but not male conceptuses and there is no change in glucose and 522 
SNAT/Slc38a amino acid transporters irrespective of fetal sex (Cuffe et al., 2011). In mice, placental 523 
Igf2 expression is unaffected by maternal administration of corticosterone and dexamethasone even 524 
though the conceptus may be growth-restricted (Cuffe et al., 2011; Vaughan et al., 2012; Vaughan et 525 
al., 2015). Whereas restrain stress increases placental Igf2 but does not alter offspring weight in 526 
mice (Pankevich et al., 2009). In rats, dexamethasone decreases placental Igf2 and the level of 527 
activated AKT, particularly in the endocrine Jz (Ain et al., 2005). In dexamethasone-treated rats, 528 
there are reductions in the expression of prolactin-related family genes by the Jz in late gestation, 529 
which may influence the maternal adaptations to pregnancy and, thus, alter the fetal supply of 530 
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nutrients indirectly (Ain et al., 2005). The expression of Igf2 by the term human placenta is also 531 
altered in women with elevated plasma cortisol during pregnancy due to emotional distress (Mina et 532 
al., 2015). Glucocorticoid response elements have been identified in the human Igf1 gene promoter 533 
(He et al., 2016) however, very little is known about whether glucocorticoids could have direct 534 
effects on placental Igf2 expression. Collectively these findings suggest that reductions in placental 535 
Igf2 system and the functional phenotype of the placenta could link elevated maternal 536 
glucocorticoids to decreases in fetal growth.  537 
 538 
In rats, pre-existing maternal diabetes also alters the expression of the IGF system in the placenta, as 539 
well as, materno-fetal resource allocation, however, the direction of change depends on how long 540 
the dam was insulin deficient/dysglycemic. For instance, Igf expression and IGF1R activation are 541 
elevated in association with greater glycerol and free fatty acid transfer by the placenta and an 542 
increase in fetal weight by 13% in rats that are diabetic from neonatal life (White et al., 2015). 543 
Placental lipid transport capacity is also increased in rat dams that are diabetic for 1 week prior to 544 
pregnancy (increase in placental lipoprotein lipase), however, the expression of Igf2 and the IGF 545 
signalling machinery is decreased and the abundance of GLUT1/Slc2a1 reduced in association with a 546 
more minor increase in fetal weight (by 5%) (Cisse et al., 2013). Genetically-inducing maternal insulin 547 
insensitivity by a global heterozygous deficiency in PI3K-p110α signalling capacity in the mouse dam 548 
is associated with improved placental Lz development (larger surface area and thinner barrier to 549 
diffusion), but reduced glucose transport and expression of nutrient (GLUT1/Slc2a1, SNAT1/Slc38a1, 550 
SNAT2/Slc38a2) and prolactin-related family genes near term (Sferruzzi-Perri et al., 2016). However, 551 
the specific nature of these placental changes depended on whether the conceptus itself was 552 
heterozygous for the PI3K-p110α deficiency (Sferruzzi-Perri et al., 2016). Moreover, there is no 553 
effect of maternal heterozygous deficiency in PI3K-p110α signalling on fetal weight in this model, 554 
irrespective of fetal genotype (Sferruzzi-Perri et al., 2016). Taken together, these studies suggest 555 
that the IGF2/PI3K-p110α system plays an important role in modulating fetal nutrition and growth in 556 
response to maternal insulin deficiency and/or insensitivity, by acting at the level of placental 557 
transport phenotype. 558 
 559 
 560 
Other environmental challenges affecting conceptus growth 561 
The expression of Igfs, receptors and signalling machinery in the placenta also changes in response 562 
insults that affect the placental capacity to supply the fetus with nutrients. Such insults include 563 
reduced utero-placental blood flow, heat stress and alcohol consumption (Table 3). Reducing both 564 
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maternal oxygen and nutrient supply to the conceptus using uterine artery ligation in mice, rats and 565 
guinea pigs, or placental embolism in sheep, reduces placental expression of components of the IGF 566 
system in association with defects in placental Lz structure and in transporter expression and activity 567 
of the glucose and Systems A and L amino acid transporters (Table 3). The extent of these changes 568 
however, depends on timing of the insult in the pregnancy. In sheep, removal of uterine caruncles 569 
prior to pregnancy is associated with increased placental Igf2 expression and an adaptive increase in 570 
placentome size, trophoblast and maternal capillary volume and surface area, although total 571 
placental mass and fetal weight, are reduced [Table 3; (Zhang et al., 2016b)]. Acute exogenous IGF1 572 
does not alter nutrient metabolism by the embolised sheep placenta [Table 1; (Jensen et al., 1999)]. 573 
However, several doses of intra-amniotic IGF1 increases glucose and Systems A and L amino acid 574 
transporter expression by the embolised placenta and improves feto-placental growth in vivo [Table 575 
1; (Eremia et al., 2007; Wali et al., 2012)]. Moreover, in mice with uterine artery ligation, targeting of 576 
IGF1 to the placenta using a nanoparticle or adenoviral-mediated approach increases the abundance 577 
of glucose and Systems A and L amino acid transporters in the placenta, placental width and fetal 578 
growth [Table 1; (Jones et al., 2013; Jones et al., 2014; Abd Ellah et al., 2015)]. These findings 579 
highlight the therapeutic potential of IGFs for improving the capacity of the placenta to supply 580 
nutrients to the fetus in compromised pregnancies.  581 
 582 
 583 
In ewes, heat stress reduces placental growth and glucose transport capacity, as well as, alters the 584 
expression of IGF1 and IGF2, and AKT, mTORC1 and MAPK signalling pathways during gestation 585 
(Table 3). In rats, alcohol consumption during the peri-conceptional period leads to late gestational 586 
fetal growth restriction but no change in placental weight (Gardebjer et al., 2014). However, Lz 587 
development and Igf1, Igf1r and SNAT2/Slc38a2 expression is decreased, but Jz glycogen cell 588 
formation, Igf2 and GLUT1/Slc2a1 may be increased in response to peri-conceptional alcohol 589 
exposure near term (Gardebjer et al., 2014). This suggests there can be programmed changes in the 590 
conceptus leading to changes in the IGF system and the structural and functional phenotype of the 591 
placenta that link the maternal environment from the earliest stages of pregnancy to fetal growth 592 
near term. 593 
 594 
CONCLUSIONS AND PERSPECTIVES 595 
Thus, IGFs are important regulators of placental resource allocation to fetal growth both 596 
developmentally and in response to environmental manipulations known to program the ill health of 597 
offspring. They increase placental morphogenesis, substrate transport and hormone secretion, 598 
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which, in turn promotes fetal growth either directly via the supply of nutrients and oxygen or 599 
indirectly via the maternal metabolic adaptation to pregnancy and the availability of nutrients for 600 
transplacental transport. In response to environmental challenges, the IGFs (particularly IGF2) and 601 
their signalling pathways change in line with the alterations in placental structure and function, and 602 
thereby, link changes in the maternal environment to fetal substrate supply and growth during 603 
pregnancy with implications for developmental programming. The environmentally-induced changes 604 
in the IGF system and placental phenotype may be beneficial (obesogenic diets, moderate hypoxia) 605 
or detrimental (eg. severe oxygen and nutrient deprivation and glucocorticoid excess) to resource 606 
allocation to the fetus depending on the type, severity and timing of the challenge during pregnancy 607 
(Figure 3). The beneficial effects of IGF treatments on placental phenotype show promising 608 
therapeutic potential for improving fetal growth in situations in which placental growth is impaired 609 
without major maternal compromise, particularly when the treatment with IGF1 or IGF2 is targeted 610 
directly to the placenta. However, efforts to understand the regulation of endogenous placental IGF 611 
expression may also be fruitful, particularly in the case of Igf2 which appears to be most important 612 
for mediating adaptive responses locally in mice. These findings are important in the context of 613 
human pregnancy as dysregulated expression of the IGFs and signalling components are often 614 
reported in the human placenta associated with abnormal fetal growth (Abu-Amero et al., 1998; 615 
Sheikh et al., 2001; Gratton et al., 2002; Gurel et al., 2003; Laviola et al., 2005; Scioscia et al., 2006; 616 
Street et al., 2006; Trollmann et al., 2007; Akram et al., 2008; Yung et al., 2008; Colomiere et al., 617 
2009; Borzsonyi et al., 2011; Street et al., 2011; Demendi et al., 2012; Jansson et al., 2012a; Iniguez 618 
et al., 2014; Nawathe et al., 2016; Zhang et al., 2016a). However, it is important to note, that several 619 
causes of environmental, maternal, and fetal origin, can lead to changes in placental phenotype and 620 
fetal growth in humans (Gaccioli & Lager, 2016). Thus studies of animal models showing alterations 621 
in the expression of IGFs and their signalling pathways provides insight but further information is 622 
required on the natural conditions of variable placental phenotype among humans. 623 
 624 
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Abstract figure. The proposed actions of IGFs on placental resource allocation to drive fetal 1490 
growth. Note that changes in placental IGFs and resource allocation depend on the timing and 1491 
severity of the environmental insult. 1492 
 1493 
Figure 1. Impact of exogenous IGFs on the placenta. A) The effect of exogenous IGFs on placental 1494 
human trophoblast in vitro. Proposed signalling pathways mediating the actions of IGFs shown. B) 1495 
The effect of exogenous maternal IGFs on the mouse, rat and/or guinea pig placenta in vivo. Dashed 1496 
lines indicate a potential interaction (A) or impact (B) of IGF1. IGF = insulin-like growth factor, IGF1R 1497 
= type 1 IGF receptor, IGF2R = type 2 IGF receptor, INSR = insulin receptor, Jz = junctional zone, Lz = 1498 
labyrinthine zone, MAPK = mitogen-activated protein kinase, PI3K = phosphoinositol 3-kinase. 1499 
 1500 
Figure 2. The effect of genetically manipulating IGF2 expression or signalling on placental 1501 
phenotype in mice. A) shows the effect of complete loss of IGF2 and B) shows the effect of partial 1502 
loss of IGF2, either by deleting the placental-exclusive isoform, Igf2P0 or through a constitutive 1503 
heterozygous deficiency of PI3K-p110α. Dashed line indicates a potential interaction of IGF2 with 1504 
receptor. Line with a round head indicates parameters reduced by loss of IGF2 signalling. Loss of 1505 
IGF2 signalling leads to reductions in placental development and transport function (A). Partial loss of 1506 
IGF2 signalling also leads to reductions in placental development, but is associated with adaptive up-1507 
regulation in transport function (B). AA = amino acids, IGF = insulin-like growth factor, IGF1R = type 1 1508 
IGF receptor, Lz = labyrinthine zone, MAPK = mitogen-activated protein kinase, PI3K = 1509 
phosphoinositol 3-kinase, XRp = unknown placental-specific IGF receptor. 1510 
 1511 
Figure 3. The effect of different environmental manipulations on the placental IGF system and 1512 
resource allocation phenotype in the mouse. A) shows manipulations which down-regulate IGF2 1513 
40 
 
signalling. B) shows manipulations which up-regulate IGF2 signalling. AKT = protein kinase B, IGF = 1514 
insulin-like growth factor, Lz = labyrinthine zone. * Note Igf2P0 is required for the placenta to up-1515 
regulate amino acid transport to the fetus in response to maternal undernutrition. 1516 
 1517 
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 1521 
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Table 1. The impact of exogenous IGF1 or IGF2 on the placental phenotype and fetal outcome (where available)  1532 
IGF System Species Treatment Study  Placental size and morphology Placental function Fetal weight References 
IGF1  
 
In vitro Mouse Primary ectoplacental 
cone trophoblast 
First 
trimester 
↑ proliferation and migration   (Kanai-Azuma et al., 
1993) 
  Pig Primary trophoblast 
cells 
First 
trimester 
↑ proliferation and migration   (Jeong et al., 2014) 
  Human  1st trimester primary 
trophoblast 
First 
trimester 
↑ invasion via INSR and IGF1R 
activation of Akt 
  (Mayama et al., 
2013) 
  Human  1st trimester placental 
explant  
 
First 
trimester 
↑ proliferation and syncytial 
formation via IGF1R-mediated 
MAPK signalling,↓ apoptosis via 
IGF1R-mediated PI3K signalling 
  (Forbes et al., 2008; 
Forbes et al., 2015) 
  Human  1st trimester placental 
trophoblast 
 
First 
trimester 
↑ proliferation, migration   (Hashimoto et al., 
2010) 
  Human  1st trimester placental 
explant 
 
First 
trimester 
↑ proliferation   (Forbes et al., 2009; 
Forbes et al., 2015) 
  Human  1st trimester placental 
explant 
First 
trimester 
↑ migration   (Lacey et al., 2002) 
42 
 
  Human  1st trimester placental 
explant 
First 
trimester 
↑ proliferation 
 
↑hCG, hPL  (Maruo et al., 1995) 
  Human  1st trimester 
trophoblast 
First 
trimester 
 ↑System A amino acid and 
glucose uptake 
 (Kniss et al., 1994) 
 
  Human  1st trimester primary 
placental fibroblasts 
First 
trimester 
↑proliferation, invasion, ↓ 
apoptosis 
  (Miller et al., 2005) 
*Ad-IGF-I 
  Human  BeWo syncytial cell 
line 
 
 ↑ proliferation, invasion, ↓ 
apoptosis 
 
↑ System A and System L 
amino acid transporter 
activity, Snat1, Snat2, Lat1, 
4F2hc, GLUT1, GLUT3 and 
GLUT8, ↓Lat2 
 (Jones et al., 2013; 
Jones et al., 2014) 
*Ad-hIGF-I 
 
  Human  BeWo    ↔ pGH  (Zeck et al., 2008) 
  Human  JEG-3 
choriocarcinoma cell 
line 
 ↑proliferation, ↓apoptosis ↑ P4, hCG secretion  (Rak-Mardyla & 
Gregoraszczuk, 
2010) 
  Human  JEG-3  
 
 ↑invasion via induction of 
adhesion and migration through 
IGF1R-PI3K and MAPK signalling 
  (Diaz et al., 2007) 
  Human BeWo 
 
  ↑ System A amino acid 
transporter activity via PI3K 
signalling, ↔ Snat1 or 
 (Fang et al., 2006)  
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Snat2 
  Human BeWo, term explants 
and term perfused 
human placenta 
  ↑ glucose transport, GLUT1 
membrane abundance  
 (Baumann et al., 
2014) 
  human Term human placenta Term  ↓ LPL activity in   (Magnusson-Olsson 
et al., 2006) 
  Human  Term trophoblast 
 
Term   ↑System A amino acid 
uptake 
 (Bloxam et al., 1994; 
Karl, 1995; Yu et al., 
1998) 
  Human  Term trophoblast and 
cell lines 
 
Term  ↑ syncytialisation   (Bhaumick et al., 
1992; Milio et al., 
1994; Cohran et al., 
1996) 
IGF2 In vitro Mouse Primary ectoplacental 
cone trophoblast 
First 
trimester 
↑ differentiation into endocrine 
cells 
  (Kanai-Azuma et al., 
1993) 
  Sheep  Primary trophoblast First 
trimester 
↑ migration    (Kim et al., 2008) 
  Human  1st trimester 
HTR8_SVneo cell line 
First 
trimester 
↑ migration via Rho GTPases   (Qiu et al., 2005; 
Shields et al., 2007)  
  Human  1st trimester 
HTR8_SVneo cell line 
First 
trimester 
↑ migration via signalling through 
IGF2R involving inhibitory G 
proteins and the MAPK pathway 
  (McKinnon et al., 
2001) 
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  Human  1st trimester primary 
trophoblast 
 
First 
trimester 
↑ migration/invasion   (Irving & Lala, 1995; 
Hamilton et al., 
1998) 
  Human  1st trimester placental 
explant 
First 
trimester 
↑ trophoblast proliferation and 
syncytial formation via IGF1R-
mediated MAPK signalling, ↓ 
apoptosis via IGF1R-mediated 
PI3K signalling 
  (Forbes et al., 2008; 
Forbes et al., 2009; 
Forbes et al., 2015) 
  Human  JEG-3 
choriocarcinoma cell 
line 
 
 ↑ invasion via induction of 
adhesion and migration through 
INSR-PI3K and MAPK signalling 
  (Diaz et al., 2007) 
  Human  SGHPL4 and 1st 
trimester villous 
explants 
First 
trimester 
↑ proliferation, migration and 
invasion 
  (Pollheimer et al., 
2011) 
  Human  1st trimester primary 
placental fibroblasts 
First 
trimester 
↑ proliferation and invasion, ↓ 
apoptosis 
  (Miller et al., 2005) 
*Ad-IGF-II 
  Human  1st trimester and term 
trophoblast 
 
First 
trimester 
↓ apoptosis, ↑proliferation and 
survival against TNF-α and IFN-γ-
induced apoptosis 
  (Hills et al., 2012) 
  Human  1st trimester placental First  ↑ glucose uptake  (Kniss et al., 1994) 
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trophoblast 
 
trimester 
  Human  1st trimester placental 
trophoblast 
 
First 
trimester 
 ↑ glucose and System A 
amino acid uptake 
 (Kniss et al., 1994) 
  Human  1st trimester placental 
explant 
First 
trimester 
↑ migration   (Lacey et al., 2002) 
  Human  In BeWo and term 
explants 
 ↑ proliferation 
↓ apoptosis and necrosis 
  (Harris et al., 2011) 
 
IGF1 In vivo 
 
Mouse D14 D17  ↔ weight, ↑ placental cross-
sectional area, Lz and fetal and 
maternal facing areas 
 ↔  weight or viability 
 
(Katz et al., 2009) 
* Ad-hIGF-I 
 
 Mouse uterine 
artery ligation 
D16 
 
D20  ↔ weight, ↑placental thickness  ↑27%, ↔ fetal 
viability 
(Abd Ellah et al., 
2015) 
* nanoparticle 
targeted delivery to 
placenta: PLAC1-
hIGF-1 
 Mouse uterine 
artery ligation 
D18  
 
D20  ND ↑4F2hc, Lat1, Lat2, GLUT8, 
GLUT9a/b, ↔ Snat1, Snat2, 
ND (Jones et al., 2013; 
Jones et al., 2014) 
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GLUT1 * Ad-hIGF-I 
 
 Guinea pig D20-37 D40  ↔ weight 
 
 ↑ 6%, ↓ litter size (Sohlstrom et al., 
2001) 
 
 
 Guinea pig D20-38 
 
D35  ↑ 17% weight, ↓ placental and Lz 
area, ↔ Lz, Jz, FC, MBS, Troph Vd 
↑ glucose and System A 
amino acid transfer, Snat2 
and prorenin activation, ↓ 
Igf2, ↔ Glut1, Igf1 
↑ 15%  (Sferruzzi-Perri et al., 
2007b; Standen et 
al., 2015) 
 Guinea pig D20-38 
 
D62  ↔ weight 
↔ structure 
↑ glucose and System A 
amino acid transfer 
↑ 17%  
↑ fetal viability 
 
(Sferruzzi-Perri et al., 
2006; Sferruzzi-Perri 
et al., 2007a) 
 Guinea pig 
30%UN 
D20-37 D40  ↑ 13% weight  
 
 ↔  (Sohlstrom et al., 
2001) 
 
  Rabbit  
Natural runt in 
litter 
D19 D21  ↔ weight  ↑ 19%  
 
(Keswani et al., 
2015) 
* Ad-hIGF-I 
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  Sheep D128, 4hr infusion D128 ND ↑ glucose transfer and 
lactate production, ↔ 
blood flow, urea or glucose 
transfer  
ND (Liu et al., 1994) 
  Sheep 
* Fetal infusion 
D121-132 D132 ↔ weight, ↓ placentome number  ↓ glucose and System A 
amino acid transfer 
↔  (Bloomfield et al., 
2002b) 
  Sheep 
* Fetal infusion 
D128, 4hr infusion D128 ND ↓ glucose transfer, lactate 
uptake and umbilical flow, 
↔ urea transfer or serine 
uptake 
ND (Harding et al., 1994; 
Jensen et al., 1999; 
Jensen et al., 2000) 
  Sheep 
Embolised 
* Fetal infusion 
D128, 4hr infusion D128 ND ↔ glucose or urea transfer, 
lactate uptake and 
umbilical flow 
ND (Jensen et al., 1999) 
  Sheep 
Spontaneous 
growth 
restriction 
* Fetal infusion 
D128, 4hr infusion D128 ND ↔ glucose or urea transfer, 
lactate uptake and 
umbilical flow 
ND (Jensen et al., 1999) 
  Sheep 
Embolised 
* Intra-
D110, D117, D124 D120-131 ↔ but placentas no longer 
significantly different to 
untreated controls 
↔ glucose uptake, ↑ Glut1, 
Glut4, Systems y+ and L 
transporters (Slc7a1 and 
↔ weight, ↑ fetal 
growth rate and 
fetuses no longer 
significantly different 
(Eremia et al., 2007; 
Wali et al., 2012) 
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amniotic 
infusion 
Slc7a8) 
↔ Glut3, Snat4, Slc7a5 
to untreated controls 
IGF2 In vivo  Mouse  D14, D16, D18  
IGF2 (1mg/kg/day) or 
iRGD-liposome with 
IGF2 (0.3mg/kg/day) 
D18  ↑ weight  ↔  (King et al., 2016) 
  Mouse IGF2P0 D14, D16, D18  
treatment with iRGD-
liposome with IGF2 
(0.3mg/kg/day) 
D18  ↔ weight of Igf2P0 and WT  ↑ Igf2P0 but not WT (King et al., 2016) 
 Rat 
 
D16-22 D22  ↔ weight, ↑ Jz  ↔  (Van Mieghem et al., 
2009) 
 Guinea pig D20-37  D40  ↑ 9% weight 
 
 ↑ 7%  (Sohlstrom et al., 
2001) 
 Guinea pig D20-38 D35  ↔ weight and structure 
 
↔ glucose or System A 
amino acid transfer, Glut1, 
Snat2, Igf1 and 
Igf2,↑prorenin activation 
↔  
 
 
(Sferruzzi-Perri et al., 
2007b; Standen et 
al., 2015) 
 Guinea pig D20-38 D62  ↔ weight, ↑ Lz area, Vd, Vol, SA, 
↓ Jz Vd, ↔ BT 
↑ glucose transfer, ↔ 
System A amino acid 
transfer 
↑ 11%  weight and ↑ 
fetal viability 
(Sferruzzi-Perri et al., 
2006; Sferruzzi-Perri 
et al., 2007a) 
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 Guinea pig 
30%UN 
D20-37 D40  ↔ weight 
 
 ↔  (Sohlstrom et al., 
2001) 
 
Leu-
27 
IGF-II 
In vivo Mouse 
 
D13-19 D19  ↔ weight 
 
↔ System A amino acid 
transfer, ↓ litter System A 
amino acid variability 
↔ weight, ↓ 
variability in fetal 
weight 
  
(Charnock et al., 
2016) 
  Mouse 
eNOS-/- 
D13-19 D19  ↔ weight 
 
 ↑  (Charnock et al., 
2016) 
  Guinea pig D20-38  D62  ↔ weight, ↑ Lz vd, Troph, MBS 
Vd and Vol and SA, ↓ Jz area, Vd, 
Vol, FC Vd, Vol and BT 
↑ glucose and System A 
transfer and prorenin 
activation 
↑ 11%  (Sferruzzi-Perri et al., 
2008) 
For in vivo studies, exogenous IGF was administered to the mother, unless stated otherwise. Abbreviations: BT=barrier thickness, D=day, FC=fetal capillaries, GLUT=glucose transporter, 1533 
hCG=human chorionic gonadotrophin, hPL=human placental lactogen, IGF1/Igf1=insulin-like growth factor-1, IGF2/Igf2=insulin-like growth factor-2, Jz=junctional zone, LAT=cationic amino 1534 
acid transporter, Lz=labyrinthine zone, MAPK/ERK=mitogen activated kinase, MBS=maternal blood space, ND=not determined; P4=progesterone; PI3K=phosphoinositol 3-kinase, 1535 
pGH=placental growth hormone, Prl=prolactin-related hormone, SA=surface area, SNAT/Slc38a= Sodium-coupled neutral amino acid transporter, vol=volume, vd=volume density. 1536 
Search terms used: trophoblast, placenta, fetus, insulin-like growth factor, IGF and/or transport 1537 
  1538 
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Table 2. The effect of genetically manipulating IGF abundance and/or signalling on feto-placental growth in mice 1539 
Manipulation Approach Placental Fetal weight Reference 
size  morphology function  
Deficiency of IGF and downstream signalling 
Global IGF1 KO Igf1-/- D18/19 ↔   D18/19 ↓40% (Baker et al., 1993) 
Global IGF2 KO Paternal Igf2- D15 ↓47% 
 
 
 
D18/19 ↓20-30% 
D15 ↓ Jz GlyT 
 
 
 
D18/19 ↔ Lz and Jz Vd 
↓ Jz GlyT 
D17 ↓ EAAT1, EAAT2 
(Jz), EAAT3 (Jz), EAAT4,↑ 
CAT1, ↔ 4f2hc 
 
D18/19 ND 
D15 ND 
 
 
 
D18/19 ↓40% 
↑ fetal loss 
(DeChiara et al., 1990; 
DeChiara et al., 1991; 
Baker et al., 1993; Liu et 
al., 1993; Lopez et al., 
1996; Matthews et al., 
1999; Esquiliano et al., 
2009; Church et al., 
2012; Kent et al., 2012) 
Global IGF2 KO Paternal transmission 
LacZDMR2– 
D16 ↓27% 
 
 
 
D19 ↓40% 
D16 ND 
 
 
 
D19 ↓ Lz vd and volume 
of all Lz components, 
SA, FC length and 
diffusing capacity, ↑ Jz 
vd and BT 
D16 ↔ System A and 
glucose transport, 
Snat1, Snat2, Snat4 
 
D19 ↓ System A transfer 
and passive 
permeability and Snat2, 
↔ glucose transport, 
Snat1 and Snat4 
D16 ↓24% 
 
 
 
D19 ↓52% 
(Constancia et al., 2005; 
Coan et al., 2008b)  
Fetal specific IGF2 KO Inner cell mass Igf2- D17 ↓14%   D17 ↓27% (Gardner et al., 1999) 
Placental trophoblast 
specific IGF2 KO 
Trophechoderm Igf2- D17 ↓21%   D17 ↓12% (Gardner et al., 1999) 
Placental Lz specific Paternal transmission D16 ↓20% D16 ↔ Lz or Jz Vd D16 ↑ System A and D16 ↔/↓4% (Constancia et al., 2002; 
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IGF2 KO  
 
Igf2P0- D17 ↓24% 
 
 
 
 
D19 ↓35% 
↓ Lz Trophoblast, GlyT 
 
 
 
 
D19 ↓ SA, trophoblast, 
FC volume, FC length, 
diffusing capacity, ↑ BT 
↔ Lz or Jz vd and 
umbilical artery flow 
 
glucose transport, 
Snat4, Glut3, ↓ passive 
permeability, calbindin, 
↔ Snat1, Snat2, Glut1 
 
D19 ↑/↔ System A 
transport, ↑glucose and 
calcium transport, ↓ 
passive permeability, ↔ 
Snat1, Snat2, Snat4, 
calcium transport, 
calbindin, PMCA1, 
TRPV6 
D17 ↓24% 
 
 
 
 
D19 ↓24% 
Sibley et al., 2004; 
Constancia et al., 2005; 
Coan et al., 2008b; 
Dilworth et al., 2010; 
Kusinski et al., 2011; 
Sferruzzi-Perri et al., 
2011; Dilworth et al., 
2013) 
 
Global IGF1R KO Igf1r- D19 ↔ D18/19  ↔ Jz GlyT D17 ↓ EAAT2 (Jz), EAAT3 
(Lz and Jz), ↑ CAT1, ↔ 
EAAT1,EAAT4 
D19 ↓55% (DeChiara et al., 1990; 
Louvi et al., 1997; 
Matthews et al., 1999) 
(Esquiliano et al., 2009) 
Global INSR KO INSR- D15 ↔ 
D18/19 ↔ 
D15 ↔ Jz GlyT 
D18/19  ↔Jz GlyT 
 D15 ND 
D18/19 ↓10% 
(Louvi et al., 1997; 
Esquiliano et al., 2009) 
 
 
PI3K p110α (Pik3ca) Kinase dead 
heterozygote Pik3ca-
D933A 
D16 ↓9% 
 
 
 
 
D16 ↓Lz vol, FC vol, FC 
length, MBS vol, SA, 
diffusing capacity, ↑ BT, 
↔ Jz  
 
D16 ↑ glucose and 
System A transfer per 
unit SA, ↔ Glut1, Glut3, 
Snat1, Snat2, Snat4  
 
D16 ↓19% 
 
 
 
 
(Sferruzzi-Perri et al., 
2016) 
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D19 ↓12% D19 ↓ Lz vol, FC vol, FC 
length, Troph vol, SA, 
diffusing capacity, ↑ BT, 
↔ Jz  
D19 ↑ glucose and 
System A transfer per 
unit SA, ↑ Prl3b1, ↔ 
Glut1, Glut3, Snat1, 
Snat2, Snat4 
D19 ↓11% 
Global decreased AKT 
signalling through 
increased PTEN  
Prl2-/- D17 ↓22% D17 ↓Jz, GlyT and Lz  D17 ↓ passive transport  D17 ↓17% (Dong et al., 2012) 
Global decreased AKT1 
signalling 
Pkba-/- 
(exons 4-8 deleted) 
D17 ↓33% 
 
D19 ↓45% 
D17 ↓ thickness, GlyT, Lz 
vessel density, length, 
area 
 
D17 ↓ pAkt 
 
D19 ↓ total Akt, pAkt 
↑ Akt2 and Akt3 
D17 ↓17% (Yang et al., 2003; Yung 
et al., 2008)  
 
Global decreased AKT1 
signalling 
Pkba-/- 
(exon 1 deleted) 
D18 ↓30% D18 ↔ Lz and Jz Vd D18 ↓ pAkt, ↔ p-Akt 
 
D18 ↓22% weight and ↑ 
fetal loss 
(Cho et al., 2001; Kent 
et al., 2012)  
Global decreased MAPK 
signalling 
Erk2-/- D11 ↓ D11 ↓ Lz thickness, FC 
development 
↓ MAPK signalling D11 ↓ weight and ↑ 
fetal loss 
(Hatano et al., 2003) 
 
Over-expression of IGF and downstream signalling 
Global IGF2 over-
expression 
Maternal Igf2r- D16 ↑40% 
D18 ↑25% 
  D16 ↑40% 
D18 ↑40% 
(Ludwig et al., 1996; 
Louvi et al., 1997) 
Global IGF2 over-
expression* 
 
Maternal H19∆13- 
 
 
 
D15 ↑37% 
 
D16 ↑30% 
 
 
 
 
D15 ↑ Jz GlyT 
 
D16 ↑ volume of all 
placental components, 
↑ SA, diffusing capacity, 
↔BT 
 
D15 ↑ Akt1 
↔ pAkt, p-ERK1/2 
D16 ↓ glucose transfer, 
passive permeability 
and Glut3, ↔Glut1, 
Snat1, Snat2, Snat4 
 
D15 ↑30% 
 
D16 ↑12% 
 
 
 
 
(Leighton et al., 1995; 
Esquiliano et al., 2009; 
Angiolini et al., 2011; 
Church et al., 2012) 
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D18 ↑60% 
 
D19 ↑45% 
D18 ↑Jz GlyT 
 
D19 ↑ volume of all 
placental components, 
SA, diffusing capacity 
 
 
D19 ↓ glucose and 
System A transfer, 
passive permeability 
and Snat4, ↔ Glut1, 
Glut3, Snat1, Snat2 
D18 ↑20% 
 
D19 ↑23% 
Global increased IGF2 
and signalling via AKT 
Double KO of maternal 
H19 and Pten +/- 
D16 ↑65% 
D19 ↑80% 
D16 ↑ Jz, GlyT 
D19 ↑ Jz, GlyT 
↑ p-AKT and IGF2 D16 ↑31% 
D19 ↑31% 
(Church et al., 2012) 
 
Global increased pAKT Pten +/- D16 ↑22% 
D19 ↑22% 
D16 ↑ Jz, GlyT 
D19 ↑ Jz, GlyT 
↑ p-AKT, ↔ IGF2 D16 ↑19% 
D19 ↑7% 
(Church et al., 2012) 
*H19 null has biallelic expression of Igf2 combined with absence miR675 (encoded by H19) 1540 
Abbreviations: BT=barrier thickness, D=day, FC=fetal capillaries, GLUT/Slc2a=glucose transporter, GlyT=trophoblast glycogen cells, IGF1/Igf1 =insulin-like growth factor-1, IGF2/Igf2=insulin-1541 
like growth factor-2, Jz=junctional zone, LAT=L-type amino acid transporter, Lz=labyrinthine zone, MBS=maternal blood space, ND=not determined, PI3K=phosphoinositol 3-kinase, SA=surface 1542 
area, SNAT/Slc38a= Sodium-coupled neutral amino acid transporter, Vd=volume density. 1543 
Search terms used: placenta, fetus, insulin-like growth factor, IGF, PI3K, ERK, MAPK, knock out, deficiency and/or transgenic 1544 
 1545 
  1546 
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Table 3. The effect of maternal environmental challenge on fetal growth and placental structure, function and IGF signalling. 1547 
Maternal manipulation  Species Timing Placental     Fetal weight Reference 
 IGF and signalling size  morphology function  
Nutrient restriction         
20% UN  Mouse  D3-D19 D16 ↑ IGF1R  
↓ Igf2P0 and PI3K 
signalling  
D19 ↓ Igf2P0 and PI3K 
signalling 
D16 ↓6% 
 
 
D19 ↓9% 
D16 ↔Lz but ↓Jz 
and GlyT 
 
D19 ↓Lz (MBS and 
FC vols and SA), ↔BT 
D16 ↓ Glut1 
 
 
D19 ↑ System 
A amino acid 
transport, ↑ 
Glut1, Snat2, 
↓Snat4 
D16 ↔ 
 
 
D19 ↓13% 
(Coan et al., 2010; 
Sferruzzi-Perri et al., 
2011) 
10-30% UN Guinea pig -D28 D35/40 ↓Igf2, ↔ Igf1 D35 ↓20%  
 
 
 
D60 ↓30% 
D35 ↓ Jz volume 
↔ Lz, but ↓ MBS, SA 
and ↑ BT 
 
D60: ↓ Lz volume, 
MBS, FC, SA, ↑ BT, ↔ 
Jz, 
 D35 ↓29%  
 
 
 
D60 ↓35% 
(Roberts et al., 2001; 
Olausson & Sohlstrom, 
2003) 
 
30% UN Sheep D22-D135 D135 ↔ Igf2 D135 ↓19% , 
altered 
placentome 
distribution 
  D135 ↓12% (Osgerby et al., 2002, 
2004) 
50% UN Sheep -D60-D30 D78 ↑ Insulin-IGF 
signalling (p-Akt and p-
D78 ↓29% D78 ↑ vascularity 
 
 D78 ↔ (Zhu et al., 2007b) 
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ERK1/2) 
 
50% UN Sheep D28-D78 D78 ↑ Insulin-IGF 
signalling (p-ERK1/2, 
↔pAkt) 
↔ mTORC1 signalling  
D135 ↔ 
D78 ↓21% 
 
 
 
D135 ↔ 
 D78 ↑Glut3, 
GLUT1, Fatp4 
 
 
D135 ↑ Fatp4 
D78 ↓26% 
 
 
 
D135 ↔ 
(Ma et al., 2011) 
 
 
UN gradual decrease to 
full food withdrawal 
Sheep  D83-D90 D90 ↔ Igf2 
 
D135 ↓Igf2 
D90 ↓22% 
 
D135 ↔ 
 D90 ↔ Glut1, 
Glut3 
D135 ↔ Glut1, 
Glut3 
D90 ↔ 
 
D135 ↔ 
(McMullen et al., 
2005) 
UN 50% Cow D30-D125 D125 ↑ Insulin-IGF 
signalling (p-Akt and p-
ERK1/2) 
D250 ↔ 
D125 ↓27%  
 
 
D250 ↓20% 
D125 ↑ vascularity 
 
 
D250 ↔ vascularity 
 D125 ↔  
 
 
D250 ↔ 
(Zhu et al., 2007a) 
70% UN Baboons 
 
D30-D165 D90 ↓ Igf2, IGF2R, 
↑ IGF1R, ↔ Igf1 or 
IGF1 
D120 ND 
 
 
 
 
 
 
 
D90 ↔ 
 
 
D120 ↔ 
 
 
 
 
 
 
 
 D90 ND 
 
 
D120 ↓ System 
A amino acid 
transport, ↔ 
system L amino 
acid transport, 
GLUT1 TAUT, 
SNAT1, SNAT2, 
SNAT4, LAT1, 
D90 ↔ 
 
 
D120 ↔ 
 
 
 
 
 
 
 
(Li et al., 2007; 
Pantham et al., 2015) 
(Kavitha et al., 2014) 
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D165 ↓ insulin/IGF-I, 
MAPK (IRS-1, Akt S6K, 
ERK-1) and mTOR 
signalling  
 
 
 
 
D165 ↓20% 
LAT2  
D165 ↓ System 
A and L amino 
acid transport, 
GLUT1, TAUT, 
SNAT2, LAT1, 
LAT 2  
 
 
 
 
D165 ↓19% 
 
 
Low protein diets         
16% v 20% protein 
(0.80CT) 
Mouse D3-19 D16 ↔ Igf2, H19 
 
 
 
 
 
 
D19 ↔ Igf2, H19 
D16 ↑5% 
 
 
 
 
 
 
D19 ↑5% 
D16 ↓ Lz/Jz ratio 
 
 
 
 
 
 
D19 ↓ Lz/Jz ratio 
D16 ↑ glucose 
transport, 
Glut1, ↔ 
System A 
amino acid 
transport 
 
D19 ↓ System 
A amino acid 
transport, 
Snat4, ↔ 
glucose 
transport, 
D16 ↔ 
 
 
 
 
 
 
D19 ↔ 
(Coan et al., 2011) 
 
8% vs 20% protein 
(0.40CT) 
Mouse  D3-19 D16 
↑ total Igf2 
↔ Igf2P0, H19  
 
 
D16 ↔ 
 
 
 
 
D16 ↔ 
 
 
 
 
D16 ↑glucose 
transport, 
Snat2, ↔ 
System A 
amino acid 
D16 ↔ 
 
 
 
 
(Coan et al., 2011) 
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D19 ↔ Igf2, H19 
 
D19 ↑4% 
 
D19 ↔ 
transport 
D19 ↓ Snat1, 
Snat4, ↔ 
glucose and 
System A 
amino acid 
transport  
 
D19 ↓9% 
9% vs 17% protein 
(0.53CT) 
Rat D1-22 D22 ↑Igf1 
↓Igf2 
↔Igf1r,Igf2r,Insr 
ND   D22 ↓8%  (Nusken et al., 2011) 
 
6% vs 20% protein 
(0.30CT) 
Rat D1-21 D14 ↓ Lz Igf2, Insr in 
female and ↑ Lz IGF2, 
↓ Igf1r in male 
 
D16 ↓ Lz Igf2 in female 
and male 
D21 ↓ Lz IGF2 in male 
and female  
D14 ↓25% 
D18 ↓12% 
 
 
 
 
 
D21 ↔ 
D14 ↓Lz and Jz vol 
D18 ↓Lz vol, ↑ 
trophoblast stem 
cells and Lz 
sinuosoidal GiT, ↓ 
spongiotrophoblast 
and GiT cells, ↔Jz 
D21↔Lz ↓Jz 
 D14 ↓21.5 
D18 ↓27 
 
 
 
 
 
D21 ↓14% 
(Gao et al., 2012a; Gao 
et al., 2012b, 2013) 
 
4% vs 18% protein 
(0.22CT) 
Rat D2-21 D19 and D21  
↓ mTOR  
 
D21 ↓ PI3K signalling 
(p-Akt-T308) 
 
D15-19 ↔ 
 
 
D21 
↓12.5% 
ND D19 and D21 
↓ Systems A 
and L amino 
acid transport, 
LAT1, LAT2, 
SNAT2, ↔ 
glucose 
transport, 
D15-19 ↔ 
 
 
D21 ↓21% 
(Jansson et al., 
2006{Rosario, 2011 
#3227; Pantham et al., 
2016) 
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SNAT4 
Obesogenic diets 
 
        
2.5-times fat Mouse -D28-D1 D13↓ Igf2, Mtor, ↔ 
Igf1 
 
D18 ↓ Igf2, Igf2r, ↔ 
Igf1  
D13 ↓20% 
 
 
D18 ↑15% in 
males, ↔ 
females 
↔ Lz D13 ↓ Snat1, 
Glut1, ↔ Cd36 
 
D18 ↓ Cd36, ↔ 
Snat1, Glut1 
D13 ↓28% 
 
 
D18 ↓15% 
(Sasson et al., 2015) 
2.5-times fat Mouse -D28-D18 D1 3↑ Igf1r, ↓ Igf2, 
Igf2r, Mtor, ↔ Igf1 
 
D18 ↓ Igf2, Igf2r, ↔ 
Igf1 
D13 ↓20% in 
males  
 
D18 ↔ 
males or 
females 
↔ Lz D13 ↓ Snat1, 
Glut1, ↔ Cd36 
 
D18 ↓ Cd36, ↔ 
Snat1, Glut1 
D13 ↓25% 
 
 
D18 ↓25% 
(Sasson et al., 2015) 
2.5-times fat Mouse D1-D18 D13 ↑ Igf1r, ↓ Igf2, 
Igf2r, Mtor, ↔ Igf1 
 
D18 ↓ Igf2, Igf2r 
↔Igf1 
D13 ↓20% in 
males  
 
D18 ↑15% in 
males  
↔ Lz D13 ↓ Snat1, 
Glut1, Cd36 
 
D18 ↓ Glut1, 
Cd36 ↔ Snat1 
D13 ↓28% 
 
 
D18 ↓28% 
(Sasson et al., 2015) 
5.3-times fat Mouse -D84-D19 D15 ↑ Igf2 and Igf2r 
male, ↔ female 
 
D19 ↔ Igf2 and Igf2r 
D15 ↔ 
 
 
 
D19 ↔ 
 D15 ↑ Lz Snat2 
in male, ↑ Lz 
Snat4 in female 
 
D19 ↔ 
D15 ↔ 
 
 
 
D19 ↓8% in males  
(King et al., 2013) 
 
 
6-times fat Mouse D1-15 D15 ↑ Igf1, ↓Irs1 in D15 ↑7% D15 ↔ Lz or D15 ↓ Slc22a1, D15 ↔ (Gallou-Kabani et al., 
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males,  ↔ Igf2, Igf2P0, 
Igf2r, H19 
vascularity 
 
↑ Slc22a2 
*sexually 
dimorphic 
response of 
placenta 
2010; Gabory et al., 
2012) 
 
2.5-times fat  Rat D1-D21 D21 ↔ mTORC1 
signalling  
D21 ↔ D21 ↓ Jz  D21 ↓5% (Mark et al., 2011) 
5-6-times fat Rat -D49-D21 D21 ↑ mTORC1 
signalling,  ↔ Insulin-
IGF signalling (p-Akt or 
p-MAPK) 
D21 ↔  D21 ↓ SNAT1, 
↔ Systems A 
and L amino 
acid transport 
and LPL 
activity, SNAT2, 
SNAT4, GLUT1, 
GLUT3, GLUT9, 
FATP4, FATP6, 
LPL 
D21 ↑7% (Gaccioli et al., 2013) 
 
3-times fat and 5-times 
sugar diet 
 
 
Mouse -D42-D18 D18 ↓ mTORC1 
signalling, ↔ Insulin-
IGF PI3K (p-AKT, IRS1, 
PI3K-p85) 
D18 ↔   D18 ↔ (Lager et al., 2014) 
 
4-times fat and 1.3-
times sugar 
 
Mouse -D20-D19 D19 ↑ Insulin/IGF-PI3K 
(p-IRS1, p-Akt-T308) 
and mTORC1 
signalling, ↔MAPK 
 
D19 ↔  D19 ↑ Systems 
A and L amino 
acid transport, 
SNAT2, LAT1, 
GLUT1, GLUT3, 
D19 ↑18% (Diaz et al., 2015; 
Rosario et al., 2015; 
Rosario et al., 2016) 
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FATP6, ↔ 
SNAT4, LAT2, 
CD98, 
FAT/CD36, 
FATP2, FATP4  
3-times fat and 5-times 
sugar diet 
Mouse D1-D19 D16 ↑ Igf2, IgfP0, H19, 
Insulin/IGF-PI3K 
signalling (PI3K-p110α, 
p-Akt), ↓ INSR, ↔ 
mTORC1 or MAPK 
 
D19 ↑ Insulin/IGF-PI3K 
signalling (PI3K-p110α, 
p-Akt, p-MAPK), ↔ 
Igf2, Igf2P0, H19, INSR 
or mTORC1  
D16 ↓11% 
 
 
 
 
 
D19 ↓8% 
D16 ↓Lz FC ↑BT 
 
 
 
 
 
D19 ↓Lz, MBS, BT, 
SA and ↓GlyT 
D16 ↑ glucose 
and System A 
amino acid 
transport, 
Glut3, Snat2 
 
D19 ↑ FATP1, 
↔ glucose and 
System A 
amino acid 
transport 
D16 ↓9% 
 
 
 
 
 
D19 ↔ 
(Sferruzzi-Perri et al., 
2013) 
50% greater food 
intake 
Sheep  -D60-D135 D70-75 ↓ p-IRS1,  
p-mTORC1, p-MAPK in 
the arterial tissues, ↔ 
INSR, IGF1R  
 
D165 ND 
 
D70-75 
↓22% 
 
  
 
D165 ↔ 
D70-75 ↑ arteriole 
diameters, ↓ vessel 
density 
 
 
D165 ↔ 
D70-75 ↑ 
Fatp1, Fatp4, 
Cd36, Lpl 
 
 
D165 ↑ GLUT3, 
FATP1, Fatp4, 
Cd36, ↔ Lpl 
D70-75 ↑20-26%  
 
 
 
 
D165 ↔ 
(Zhu et al., 2009; Ma 
et al., 2010; Zhu et al., 
2010; Tuersunjiang et 
al., 2013) 
 
Hypoxia         
13% Mouse D1-D19 D19 ↑ Insulin-IGF  D19 ↑10% D19 ↑ Maternal  ND D19 ↓12% weight and (Matheson et al., 
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(↑ p-Akt) and mTORC1 
signalling  
arterial and venous 
blood space 
litter size 2015)  
13% hypoxia Mouse D11-16 D16 ↓ Igf2, ↔ Igf2P0, 
altered p-Akt 
(depending on site 
phosphorylated) 
D16 ↔ D16 ↑ Lz  
↑ MBS, trophoblast 
vol, SA exchange 
 
D16 ↔ System 
A amino acid 
amino acid or 
glucose 
transport, 
Gluts and Snats 
D16 ↔ {Higgins, 2015 #5541 
13% hypoxia Mouse D14-19 D19 ↑ Igf2, Igf2P0, 
altered insulin-IGF 
signalling (↓ INSR, 
IGF1R, PI3K-p85α, 
PI3K-p110α but  
↑ p-Akt) 
D19 ↔ D19 ↑ FC volume 
and density, ↓ BT 
D19 ↑ glucose 
transport, 
Snat1, ↔ 
System A 
amino acid 
amino acid 
transport 
D19 ↓5% (Higgins et al., 2015) 
12% Hypoxia Mouse D14.5-18.5 D18.5 ↓ Igf2r and 
Igf2, Igf1r in females 
D18.5 ↔ D18.5 ↓Lz blood 
space, ↑tissue in 
females  
D18.5 ↓ Glut1, 
↑ Snat1 in 
females, 
↔ Glut3 
D18.5 ↓6.5% (Cuffe et al., 2014) 
 
10% hypoxia Mouse D14-19 D19 ↓ Insulin-IGF 
signalling (↓ INSR, 
IGF1R, PI3K-p85α, 
PI3K-p110α and p-
Akt), ↔ Igf2, Igf2P0 
D19 ↔ D19 ↓ Lz vd, MBS 
volume, SA 
exchange, ↑ Jz vd, 
trophoblast vol and 
BT 
D19 ↓ System 
A amino acid 
transport, ↔ 
glucose 
transport but 
altered uterine 
artery 
vasoreactivity 
D19 ↓21% (Higgins et al., 2015; 
Skeffington et al., 
2015) 
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Endocrine disruption         
Corticosterone 
83µg/g/day 
Mouse D11-D16 D16 ↓ p-Akt, ↔ Igf2, 
Igf2P0, INSR, IGF1R, 
mTORC1 signalling  
D16 ↓6% D16 ↓ FC vol and Vd, 
↑ MBS and Troph Vd, 
↔ SA, BT 
D16 ↓ Glut1, 
Glut3, Snat1, 
Snat2, ↔ 
glucose or 
System A 
amino acid 
transport and 
Snat4 
D16 ↓7% (Vaughan et al., 2012; 
Vaughan et al., 2015) 
Corticosterone 
81µg/g/day 
Mouse D11-D19 D19 ↓ mTORC1 
signalling, ↔ Igf2, 
Igf2P0, INSR, IGF1R, p-
Akt 
D19 ↓12% D19 ↔ FC, MBS, 
Troph, SA, BT 
D19 ↓ glucose 
and System A 
amino acid 
transport, ↑ 
Snat1, ↔ 
Glut1, Glut3, 
Snat2, Snat4 
D19 ↓19% (Vaughan et al., 2012; 
Vaughan et al., 2015) 
 
Dexamethasone 
24µg/kg/day 
Mouse D13-D16 D16↓ MAPK1 
D18 ↔ MAPK1  
 
D16 and D18 ↔ Igf2 
D16 ↓20% 
female only 
 
D18 ↔ 
D16↓Jz area female 
only 
 
D18 ND 
D16 and D18  
↔ Glut1, 
Glut3, Snat1, 
Snat2, Snat4 
D16 ↓20% 
 
 
D18 ↔ 
(Cuffe et al., 2011) 
Dexamethasone 
24µg/kg/day 
Rat  D13-D20 D20 ↓pAkt in Jz D20 ↓50%  D20 ↓ Prls in Jz, 
↑ Prls in Lz 
D20 ↓22% (Ain et al., 2005) 
Diabetes via 
streptozotocin 
administration 
neonatally 
Rat  D20 ↑ Igf1, Igf2, Igf2r, 
IGF1R kinase and 
autophosphorylation 
activity, ↔ Igf1r, Insr 
D21 ↑22% D21 D21↑ glycerol 
and FFA 
release 
D21 ↑13% (Hauguel-de Mouzon 
et al., 1992; Martinez 
et al., 2008; White et 
al., 2015) 
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Diabetes via 
streptozotocin 
administration 1 week 
before mating 
Rat -D7-D21 D21↓ Insr, Irs1, Igf2, 
Igf2r, ↔ Irs2, Igf1r 
D21 ↑22%  D21↑ Lz, ↑ lacunae  D21↓ Glut1,↑ 
Lpl, ↔ Glut3, 
Snat2, Snat4, 
Lat1 
D21 ↑5% or ↔  (Cisse et al., 2013) 
 
Insulin resistance via 
heterozygous p110α 
deficiency 
Mouse   D16 ↓ PI3K signalling 
 
 
 
 
 
 
 
D19 ↓ PI3K signalling 
D16 ↔ 
 
 
 
 
 
 
 
D19 ↑15% 
D16 ↓ Lz Troph vol,  
↓ BT 
 
 
 
 
 
 
D19 ↑ Jz vol 
↑ SA diffusing 
capacity 
D16 ↓ glucose 
transfer, Snat1, 
↔ System A 
amino acid 
transfer, Glut1, 
Glut3, Snat2, 
Snat4 
 
D19 ↓ glucose 
transfer, Glut1, 
Snat1, Snat2, 
Prls, ↔ System 
A amino acid 
transfer, Glut3, 
Snat4 
D16 ↔ 
 
 
 
 
 
 
 
D19 ↔ 
(Sferruzzi-Perri et al., 
2016) 
 
*Depends on fetal 
genotype 
Other manipulations 
affecting conceptus 
growth 
        
Restriction of utero-
placental blood flow 
        
Uterine ligation Mouse  D18 D20 ↓ Igf1, Igf2 D20 ↔ D20 ↓ Lz depth, vol, D20 ↓ Slc5a9, D20 ↓11% (Habli et al., 2013; 
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vessel area Slc7a10, 4F2hc, 
Lat1, Lat2, 
Snat2, GLUT1, 
GLUT8, ↑ 
Snat1, ↔ 
GLUT3, GLUT9 
Jones et al., 2013; 
Jones et al., 2014) 
Uterine ligation Rat  D17 D20 ↓ Igf2  D20 ↓8%   D20 ↓20% (Price et al., 1992) 
Uterine ligation Rat D18 or D19 D20 ↓ IGF1R, ↔ INSR D20 ↔ or 
↓25% 
D20↑ diameter, ↔ 
Lz vd 
D20 ↓ GLUT1, 
↔ GLUT3 
D20 ↓7% or 27% 
weight and ↓ litter size 
 
(Das et al., 1998; Reid 
et al., 2002; Wlodek et 
al., 2005) 
Uterine ligation Rat D19 D22 ↓ Igf1, ↔ Igf2, 
Insr, Igf1r, Igf2r 
ND   D22 ↔ (Nusken et al., 2011) 
 
Uterine ligation Guinea pig  D30 D55-60 ↔ Igf1, Igf2 D55-60 ↔ 
or 37% 
 D55-60 ↓ 
System A 
amino acid 
transfer, ↔ 
glucose 
transfer  
D55-60 ↓7% or 38% (Jansson & Persson, 
1990; Carter et al., 
2005) 
Placental embolism sheep D113-120 D131 ↓ IGF1R, ↔ IGF-I D131 ↓30%   D131 ↓21% (Bloomfield et al., 
2002a; Shaikh et al., 
2005) 
Placental embolism sheep D103-109 D131 ↔ Mtor D131 ↓43%  D131 ↓ Glut1, 
Slc7a1, Slc7a8, 
↔ Glut3, 
Glut4, Snat4, 
Slc7a5 
D131 ↓20% (Wali et al., 2012) 
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Uterine carunclectomy sheep -D70 D130-134 ↑ Igf2,  
↔ Igf1, Igf1r,Igf2r 
D130-134  
↓ 30-40% 
 
D130-134 altered 
distribution of 
placentome types 
and ↓ placentome 
number but ↑ 
individual weight of 
placentomes, 
trophoblast and 
maternal capillary 
volume and SA of 
placentomes 
D130-134  
↓ Fatp4,  
↔ Glut1, 
Glut3, Glut4, 
Slc7a1, Slc7a5, 
Snat1, Snat4, 
Fatp1, Cd36, 
Fabp5 
D130-134 ↓26% (Zhang et al., 2016b) 
Hyperthermia Sheep D39-D125 D55 ↑ IGF2  
 
D90 ↑ IGF1 ,  
p-mTORC1, ↓ p-Akt,  
↔ MAPK 
 
D135 ↑ pAkt, p-MAPK 
dys-regulated mTORC1 
signalling (↑ p-
mTORC1 but ↓ p-p70) 
D55 ↔ 
 
D90 ↓24% 
 
 
 
D135 ↓58% 
  
 
 
 
 
 
D135 ↑ Slc7a5, 
Slc7a8,  uterine 
blood flow, 
trans-placental 
oxygen 
diffusion,  
↓ branched 
amino acid and 
glucose 
transport,  
D55 ↔ 
 
D90 ↔ 
 
 
 
D135 ↓47% 
(Thureen et al., 1992; 
Ross et al., 1996; 
Anderson et al., 1997; 
Regnault et al., 2003; 
de Vrijer et al., 2004; 
Regnault et al., 2005; 
de Vrijer et al., 2006; 
Regnault et al., 2007; 
Arroyo et al., 2009; 
Arroyo et al., 2010) 
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↔ utero-
placental 
oxygen uptake 
Alcohol consumption Rat -D4-D4 D20 ↓ Lz Igf1, and Lz 
Igf1r in males, ↔ Igf2 
 
↑ Jz Igf2, ↔ Jz Igf1, Lz 
or Jz Igf2r  
D20 ↔ D20 ↑ length and 
width, ↓ Lz and ↑ Jz 
and ↑ GlyT in 
females 
D20 ↓ Lz Snat2, 
↔ Lz Snat1, 
Snat4, Glut1, 
Glut3 and ↓ Jz 
Glut1 in males, 
↑Jz Glut1 in 
females 
D20 ↓7% (Gardebjer et al., 
2014)  
 
Gestational age: mouse ~20 days, rats ~23 days, guinea pigs ~70 days, sheep ~150 days, cows ~283 days, baboons ~183 days. 1548 
Abbreviations: BT=barrier thickness, D=day, FATP=fatty acid transport protein, FC=fetal capillaries, GLUT=glucose transporter, GiT- giant trophoblast cells, GlyT- trophoblast glycogen cells, 1549 
IGF1/Igf1=insulin-like growth factor-1, IGF2/Igf2=insulin-like growth factor-2, Jz=junctional zone, LAT=cationic amino acid transporter, LPL=lipoprotein lipase, Lz=labyrinthine zone, 1550 
MAPK/ERK=mitogen activated kinase, MBS=maternal blood space, mTOR=mechanistic target of rapamycin, p=phosphorylation, PI3K=phosphoinositol 3-kinase, Prl=prolactin-related hormone, 1551 
SA=surface area, SNAT/Slc38a= Sodium-coupled neutral amino acid transporter, UN=undernutrition; vol=volume, vd=volume density. 1552 
Search terms used: placenta, fetus, insulin-like growth factor, IGF, nutrient restriction, undernutrition, low protein diet, high sugar, high fat, obesogenic, IUGR, PI, hypoxia, uterine ligation, 1553 
corticosterone, dexamethasone carunclectomy, heat stress and/or diabetes. 1554 
 1555 
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